TerminatedNCT06423794
BHV-7000 Open-Label Extension Bipolar Mania Study
Researchers are studying BHV-7000, tracking side effects to assess long-term safety and tolerability in people with bipolarity type I.
Medication studyAges 18–75United States
Understand this study
What is this study about?
Researchers are studying BHV-7000, tracking side effects to assess long-term safety and tolerability in people with bipolarity type I.
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
- Listed locations
- Bentonville and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 24, 2024
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 94
- Sponsor
- Biohaven Therapeutics Ltd.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT06423794
- Official title
Show the full official title
A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Bipolar I Disorder
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bentonville · Little Rock · Rogers
26 more locations
- Anaheim
- Bellflower
- Culver City
- Garden Grove
- Lemon Grove
- Orange
- Riverside
- Torrance
- Hollywood
- Miami
- Miami Lakes
- West Palm Beach
- Atlanta
- Decatur
- Savannah
- Chicago
- Gaithersburg
- Flowood
- St Louis
- Marlton
- Staten Island
- Dayton
- North Canton
- Austin
- DeSoto
- Richardson
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are studying BHV-7000, tracking side effects to assess long-term safety and tolerability in people with bipolarity type I.
Who is behind this study?
The study sponsor is Biohaven Therapeutics Ltd.
Does this study involve medication?
Yes. The study involves medication, including BHV-7000.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolarity type I.